Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Delivery
- Sub-Industry: N/A
- Symbol: NASDAQ:ARDM
- CUSIP: N/A
- Web: www.aradigm.com
- Market Cap: $19.39 million
- Outstanding Shares: 14,800,000
- 50 Day Moving Avg: $1.25
- 200 Day Moving Avg: $2.11
- 52 Week Range: $0.78 - $7.19
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.45
- P/E Growth: 0.00
- Annual Revenue: $1.88 million
- Price / Sales: 10.31
- Book Value: ($0.52) per share
- Price / Book: -2.51
- EBIDTA: ($24,570,000.00)
- Net Margins: -32,717.14%
- Return on Equity: -220.57%
- Return on Assets: -105.09%
- Debt-to-Equity Ratio: 1.53%
- Current Ratio: 5.27%
- Quick Ratio: 5.27%
- Average Volume: 61,176 shs.
- Beta: 1.14
- Short Ratio: 1.44
Frequently Asked Questions for Aradigm (NASDAQ:ARDM)
What is Aradigm's stock symbol?
Aradigm trades on the NASDAQ under the ticker symbol "ARDM."
How were Aradigm's earnings last quarter?
Aradigm Co. (NASDAQ:ARDM) released its quarterly earnings results on Monday, May, 15th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.18. The firm had revenue of $1.69 million for the quarter. Aradigm had a negative return on equity of 220.57% and a negative net margin of 32,717.14%. View Aradigm's Earnings History.
Are investors shorting Aradigm?
Aradigm saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 57,291 shares, an increase of 25.8% from the April 13th total of 45,532 shares. Based on an average trading volume of 38,519 shares, the short-interest ratio is presently 1.5 days.
Who are some of Aradigm's key competitors?
Some companies that are related to Aradigm include Catasys (CATS), Nivalis Therapeutics (NVLS), Chiasma (CHMA), Fibrocell Science (FCSC), Critical Outcome T (COTQF), EnteroMedics (ETRM), Ekso Bionics Holdings (EKSO), Histogenics Corp (HSGX), Electromed (ELMD), Threshold Pharmaceuticals (THLD), Soleno Therapeutics (SLNO), Biocept (BIOC), Can Fite Biopharma Ltd (CANF), Evoke Pharma (EVOK), Tonix Pharmaceuticals Holding Corp. (TNXP), Check Cap Ltd (CHEK), Alcobra Ltd (ADHD) and Dimension Therapeutics (DMTX).
Who owns Aradigm stock?
Aradigm's stock is owned by many different of retail and institutional investors. Top institutional investors include
(48.30%), First Eagle Investment Management LLC (26.05%), Boxer Capital LLC (3.89%), Paulson & CO. Inc. (1.30%), FMR LLC (0.00%) and Vanguard Group Inc. (0.00%). View Institutional Ownership Trends for Aradigm.
Who sold Aradigm stock? Who is selling Aradigm stock?
How do I buy Aradigm stock?
Shares of Aradigm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Aradigm stock cost?
One share of Aradigm stock can currently be purchased for approximately $1.31.
Consensus Ratings for Aradigm (NASDAQ:ARDM) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Aradigm (NASDAQ:ARDM)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Aradigm (NASDAQ:ARDM)Earnings History by Quarter for Aradigm (NASDAQ:ARDM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/15/2017||Q1 2017||($0.43)||($0.25)||$1.69 million||View||N/A|
|3/28/2017||Q4 2016||($0.37)||($0.54)||$0.13 million||View||N/A|
|11/9/2016||Q3 2016||($0.53)||($0.55)||$0.05 million||View||N/A|
|8/13/2015||Q2||($0.08)||($0.08)||$11.60 million||$10.00 million||View||N/A|
|3/17/2015||Q414||($0.07)||($0.06)||$6.70 million||$8.10 million||View||N/A|
|11/7/2014||Q314||($0.10)||($0.06)||$4.80 million||$6.60 million||View||N/A|
|8/7/2014||Q214||($0.09)||($0.09)||$4.25 million||$12.20 million||View||N/A|
Earnings Estimates for Aradigm (NASDAQ:ARDM)
Current Year EPS Consensus Estimate: $-1.1000 EPS
Next Year EPS Consensus Estimate: $-0.3800 EPS
Dividend History for Aradigm (NASDAQ:ARDM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aradigm (NASDAQ:ARDM)
Insider Ownership Percentage: 4.10%Insider Trades by Quarter for Aradigm (NASDAQ:ARDM)
Institutional Ownership Percentage: 43.59%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|4/4/2017||Juergen Kurt Froehlich||Insider||Sell||3,765||$1.51||$5,685.15|| |
|10/4/2016||Juergen Kurt Froehlich||Insider||Sell||423||$6.76||$2,859.48|| |
|6/21/2016||Juergen Kurt Froehlich||Insider||Sell||333||$4.45||$1,481.85|| |
|12/13/2013||Virgil Thompson||Director||Sell||3,340||$0.17||$567.80|| |
|8/27/2013||First Eagle Investment Managem||Major Shareholder||Buy||40,322,580||$0.12||$4,838,709.60|| |
|12/11/2012||First Eagle Investment Managem||Major Shareholder||Buy||41,666,667||$0.12||$5,000,000.04|| |
Headline Trends for Aradigm (NASDAQ:ARDM)
Latest Headlines for Aradigm (NASDAQ:ARDM)
Aradigm (ARDM) Chart for Wednesday, May, 24, 2017